

BIO RAD LABORATORIES INC  
 Form 4/A  
 April 13, 2006

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 SCHWARTZ NORMAN D

2. Issuer Name and Ticker or Trading Symbol  
 BIO RAD LABORATORIES INC  
 [bio bio.b]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
 1000 ALFRED NOBEL DRIVE  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 04/03/2006

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 CEO

HERCULES, CA 94547

4. If Amendment, Date Original Filed(Month/Day/Year)  
 04/05/2006

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Code V Amount (D) Price		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)

Edgar Filing: BIO RAD LABORATORIES INC - Form 4/A

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)	\$ 69.3 <sup>(1)</sup>	04/03/2006	A	1,587					04/03/2011 <sup>(2)</sup>	04/03/2011	Bio-Rad Common B	1,587
Incentive Stock Option (right to buy)	\$ 39.6								02/05/2005 <sup>(2)</sup>	02/05/2008	Bio-Rad Common B	2,955
Incentive Stock Option (right to buy)	\$ 58.85								02/04/2006 <sup>(2)</sup>	02/04/2009	Bio-Rad Common B	3,737
Incentive Stock Option (right to buy)	\$ 62.04								02/09/2010 <sup>(2)</sup>	02/09/2010	Bio-Rad Common B	1,739

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SCHWARTZ NORMAN D 1000 ALFRED NOBEL DRIVE HERCULES, CA 94547	X	X	CEO	

## Signatures

Norman D Schwartz 04/12/2006

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The exercise price has been amended as the reporting person owns greater than 10% of the total combined voting power of all classes of stock of the company and in order to be in compliance with requirements under Internal Revenue Code Section 422, the correct exercise price is \$69.30 which is 110% of the fair market value on the grant date.

(2) The "Date Exercisable" for these stock options has been amended to reflect the correct vesting dates.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.